Compare RUBI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUBI | ARTL |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.4M |
| IPO Year | 2022 | 2014 |
| Metric | RUBI | ARTL |
|---|---|---|
| Price | $1.37 | $2.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 24.3K |
| Earning Date | 11-18-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.52 |
| 52 Week High | $6.69 | $179.19 |
| Indicator | RUBI | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 39.03 |
| Support Level | $0.91 | $2.05 |
| Resistance Level | $2.01 | $6.81 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 45.74 | 44.97 |
Rubico Inc is an international provider of crude oil transportation services. The Company is engaged in the ownership and operation of a fleet of tanker vessels designed for enhanced fuel efficiency and reduced greenhouse gas emissions, incorporating environmentally friendly technologies.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.